Geordan Pursglove

Chairman of the Board of Directors and Chief Executive Officer

Mr. Pursglove, age 37, is an accomplished executive and entrepreneur with over a decade of experience across mergers and acquisitions, public and private capital markets, strategic growth, and operational leadership. His career spans multiple sectors, including technology, logistics, customer experience, sports, and marketing, where he has consistently delivered results by driving innovation, scaling operations, and building value-driven organizations. Mr. Pursglove is widely regarded for his forward-thinking leadership, entrepreneurial mindset, and deep understanding of how to build scalable infrastructure, raise capital, and execute on transformative business strategies in both public and private market environments.

Bas van der Baan

President, Chief Scientific Officer

Mr. van der Baan, 51, has more than 20 years of experience in the biotechnology industry, with a key focus on oncology and diagnostics. Most recently, he was the Chief Clinical and Business Development Officer of Agendia, Inc. in Irvine, California and Amsterdam, Netherlands. In that role, Mr. van der Baan was instrumental in the initiation and execution of numerous clinical trials that led to full commercialization and adoption of precision molecular oncology diagnostics. He initiated the launch of Agendia’s business operations in the United States and has broad knowhow in clinical development, both in the United States and in Europe.

Dr. Rene Bernards

Director

Dr. Rene Bernards is a leader in the field of molecular carcinogenesis, working at the Netherlands Cancer Institute in Amsterdam. His research focuses on identifying effective new drug combinations, new drug targets, and mechanisms of resistance to anti-cancer drugs. He has also co-founded four biotechnology companies to bring his scientific discoveries to clinical oncology practice. He is a member of the Royal Netherlands Academy of Sciences, an International Honorary Member of the American Academy of Arts and Sciences and an International Member of the National Academy of Sciences (USA). Additionally, he is a fellow of the American Association for Cancer Research (AACR), and has received the Princess Takamatsu Memorial Lectureship at this year’s AACR annual meeting where he presented new data on the unexpected effectiveness of the Company’s lead compound, LB-100, when given with a variety of standard and investigational anti-cancer compounds that have only modest activity on their own.

Regina Brown, CPA

Director

Regina Brown, CPA, began her accounting practice over 30 years ago after passing all four parts of the CPA exam in one sitting. She was subsequently honored by the California Society of Women CPA’s for this unusual achievement.

Currently, her practice has a wide range of clients, varying in size, industry and geographic locations. They include large national corporations listed on the New York Stock Exchange, as well as local Southern California businesses. Other clients consist of professionals, wholesalers, and high net worth individuals. Many of her clients have international and cross-border operations.

As a consequence of her depth of experience, she regularly assists other professionals with their clients’ issues and performs tax research and analysis in connection with litigation and other matters including marital dissolution, tax and accounting with respect to mergers and acquisitions, implementation of internal controls and extensive work in the area of trusts and estates. In addition, international tax matters and compliance have become a significant part of her practice.

Ms. Brown is a member in good standing of the California Society of CPAs (Cal CPA) and the American Institute of Certified Public Accountants (AICPSA) and has appeared as a speaker before both.

Jason Sawyer

Director

Mr. Jason Sawyer is a 30-year veteran of the alternative investment industry and General Manager of Access Alternative Group S.A. (AAG), a Nassau-based venture investment and advisory firm. Based in Cancún, Mexico, he has led over $200 million in early and growth-stage investments across sectors including fintech, biotech, software, energy, and consumer products, partnering with leading family offices and institutions. Previously a Principal at Crane Capital (sold to Bear Stearns), he co-founded Candlebrook Capital and has raised over $3.5 billion for top-tier managers including Blackstone and Gottex. He has also co-founded and financed companies such as Caary Capital, Pacific West Stone, Sanna Health, and California Fitness, with successful exits and institutional backing. He currently leads finance and M&A for Quantum BioPharma (Nasdaq: QNTM) and serves on the board of The FUTR Corp (TSX.V: FTRC).

Dr. Michael Holloway

Director

Dr. Michael Holloway is an Accomplished Emergency Medicine Physician and Medical Affairs executive. Extensive experience spanning diverse healthcare environments across British Columbia, Alberta and Ontario. Demonstrated leadership and medical innovation at VP level. . Proven track record in policy development, board governance and strategic consulting in healthcare and other fields. Complemented by a solid foundation in business administration and a commitment to volunteerism. Extensive exposure to early stage companies in multiple fields.